Panjang
On verge of major breakout
Telah dikemas kini
Recently approved ADHD med. CEO Travis Mickle helped develop current market leader Vyvance (also ADHD med) and now with a new and improved iteration (Aztrazyris) .
Also worth to note Mickle sold his previous company (new river) to shire then shire was bought out by Takeda for bucku bucks and now Mickle is working with ex-shire CEO to bring this baby to market!
Revenues on ADHD med alone could see peak sales in the Billions of $$ per year (although will take some time to get there).
KMPH recently received attention on Twitter from popular account hat shared unverified short interest thus the previous pump and dump. however, the company currently has no debt and strong balance sheet/ cash runway with the help of corium (ex-shire CEO) to get the drug to market. Mickle expects availability by Summer and sounds like they will get a favorable label 🏷 suggesting 30min onset and 13-hour duration but that has not been set in stone yet.
KMPH has multiple milestone in form of $48 Million and $450+ million which would be a major change to current valuation/ market cap.
Also worth to note, KMPh currently has very little institutional ownership as MMs fled from previous dealings, however , the company recently did an offering to clean up balance sheet and eliminate debt.
The company has begun to look fundamentally and technically attractive again and once the smoke blows over from MMs losing money previously I believe we see major accumulation from institutional investors that take this up 🚀 🚀
Catalyst:
30/13 label 🏷
$48 Mill milestone payment
Another $450+ milestone (sorry don’t have exact # rn) payment
Uptick in institutional investors will attract other investors bringing new ratings and price targets.
Also the company has other potential billion $$ blockbuster in pipeline that I’m excited about. Specifically a drug for stimulating use disorder (SUD) which would be the first of its kind helping those with cocaine, methamphetamine addiction.
Disclosure: I am long KMPH. I am not a financial advisor and this is to be used for educational purposes only. Please do your own due diligence.
Also worth to note Mickle sold his previous company (new river) to shire then shire was bought out by Takeda for bucku bucks and now Mickle is working with ex-shire CEO to bring this baby to market!
Revenues on ADHD med alone could see peak sales in the Billions of $$ per year (although will take some time to get there).
KMPH recently received attention on Twitter from popular account hat shared unverified short interest thus the previous pump and dump. however, the company currently has no debt and strong balance sheet/ cash runway with the help of corium (ex-shire CEO) to get the drug to market. Mickle expects availability by Summer and sounds like they will get a favorable label 🏷 suggesting 30min onset and 13-hour duration but that has not been set in stone yet.
KMPH has multiple milestone in form of $48 Million and $450+ million which would be a major change to current valuation/ market cap.
Also worth to note, KMPh currently has very little institutional ownership as MMs fled from previous dealings, however , the company recently did an offering to clean up balance sheet and eliminate debt.
The company has begun to look fundamentally and technically attractive again and once the smoke blows over from MMs losing money previously I believe we see major accumulation from institutional investors that take this up 🚀 🚀
Catalyst:
30/13 label 🏷
$48 Mill milestone payment
Another $450+ milestone (sorry don’t have exact # rn) payment
Uptick in institutional investors will attract other investors bringing new ratings and price targets.
Also the company has other potential billion $$ blockbuster in pipeline that I’m excited about. Specifically a drug for stimulating use disorder (SUD) which would be the first of its kind helping those with cocaine, methamphetamine addiction.
Disclosure: I am long KMPH. I am not a financial advisor and this is to be used for educational purposes only. Please do your own due diligence.
Nota
Today, Mickle PR'd updates to GPC milestones on Azstarys for the treatment of ADHD which the FDA approved March 2, 2021. Rather than 48$ Mill upfront, they will receive 10Mill within 5 calender days after the effective date of the agreement then another $10 Milly after DEA Scheduling in June. Most noteworthy, KMPH is eligible for up to $590 million in future regulatory and sales milestone payments which was previously $468 Million. Mickle stated the re-evaluation of "the commercial potential of AZSTARYS based on the final approved label, and negotiated adjustments to the economics of our License Agreement to optimize investment in the commercial launch and, ultimately, long-term value creation. The outcome is that more resources will be invested during the initial phases of the commercial timeline for AZSTARYS
**which we believe could lead to a greater market share and potentially accelerate the ramp to peak, as compared to our original forecasts**."
To put simply, after updating balance sheet and relooking @ AZSTARYS market potential, he became more bullish.
Looking for new tutes initiating coverage, new PTs, new money in upcoming months. Letssss Gooooo!
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.